Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Safety Concerns About Indevus’ Nebido Could Add 24 Months To Approval Timeline

Jun 04 2008

Related Content

Indevus Submits Nebido For Hypogonadism

Aug 28 2007

Indevus To Market Nebido In The U.S. Upon Approval

Jul 29 2005

Indevus Submits Data To FDA With New Dosing Regimen For Hypogonadism Candidate

Jan 22 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window